Edgewise Therapeutics Inc (EWTX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
CEO:
Kevin Koch
Employees:
60
C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVE, 54TH FLR., NEW YORK, NY 10022
212-739-6451

Edgewise Therapeutics, Inc. develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy.

Data derived from most recent annual or quarterly report
Market Cap 616.809 Million Shares Outstanding63.262 Million Avg 30-day Volume 179.61 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue0.0 Debt to Equity0.0 EBITDA-85.172 Million
Price to Book Value1.2832 Operating Margin0.0 Enterprise Value94.031 Million
Current Ratio26.218 EPS Growth0 Quick Ratio25.793
1 Yr BETA 1.3347 52-week High/Low 14.33 / 5.43 Profit Margin0.0
Operating Cash Flow Growth-57.1361 Altman Z-Score14.0663 Free Cash Flow to Firm -64.14 Million
Earnings Report2023-08-03

View recent insider trading info

Edgewise Therapeutics Inc YCharts
Yahoo! Finance finviz

Funds Holding EWTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EWTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

13 Thousand total shares from 6 transactions

Exercise Derivative Conversion (M)

41.7 Thousand total shares from 6 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KOCH KEVIN PRESIDENT AND CEO

  • Officer
  • Director
 303,593 2023-05-01 2

MOORE JOHN R GENERAL COUNSEL

  • Officer
 6,565 2023-05-01 10

DONOVAN JOANNE M. CMO

  • Officer
 9,960 2023-05-01 2

CARRUTHERS R MICHAEL CHIEF FINANCIAL OFFICER

  • Officer
 16,126 2023-05-01 2

DERAKHSHAN BEHRAD CHIEF BUSINESS OFFICER

  • Officer
 7,020 2023-05-01 2

RUSSELL ALAN J CHIEF SCIENTIFIC OFFICER

  • Officer
  • Director
 176,191 2023-05-01 2

FOX JONATHAN C

  • Director
 0 2023-03-03 2

SEMIGRAN MARC CHIEF DEVELOPMENT OFFICER

  • Officer
 300,000 2022-12-30 2

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

ORBIMED GENESIS GP LLC

  • Director
  • 10% Owner
 14,301,551 2022-09-16 1

THOMPSON PETER A.

  • Director
  • 10% Owner
 14,301,551 2022-09-16 2

NOVO HOLDINGS A/S

  • 10% Owner
 6,071,703 2022-09-14 1

ROOT JONATHAN D

  • Director
 57,712 2022-06-24 1

BREGE LAURA

  • Director
 42,087 2022-06-24 1

EDRIS BADREDDIN

  • Director
 42,087 2022-06-24 1

FLYNN JAMES E

DEERFIELD MGMT IV, L.P.

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD PRIVATE DESIGN FUND IV, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
 No longer subject to file 2021-03-30 0

WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.

  • 10% Owner
 No longer subject to file 2021-03-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

DONOVAN JOANNE M. - Officer CMO

2023-05-03 18:25:48 -0400 2023-05-02 S 3,254 $8.90 d 9,960 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

KOCH KEVIN - Director - Officer PRESIDENT AND CEO

2023-05-03 18:25:43 -0400 2023-05-02 S 3,203 $8.90 d 7,213 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

RUSSELL ALAN J - Director - Officer CHIEF SCIENTIFIC OFFICER

2023-05-03 18:26:08 -0400 2023-05-02 S 1,602 $8.90 d 176,191 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

DERAKHSHAN BEHRAD - Officer CHIEF BUSINESS OFFICER

2023-05-03 18:26:49 -0400 2023-05-02 S 1,747 $8.90 d 7,020 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

CARRUTHERS R MICHAEL - Officer CHIEF FINANCIAL OFFICER

2023-05-03 18:26:15 -0400 2023-05-02 S 1,336 $8.90 d 16,126 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

MOORE JOHN R - Officer GENERAL COUNSEL

2023-05-03 18:26:36 -0400 2023-05-02 S 1,897 $8.90 d 6,565 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

RUSSELL ALAN J - Director - Officer CHIEF SCIENTIFIC OFFICER

2023-05-03 18:26:08 -0400 2023-05-01 M 5,208 d 10,417 direct

RUSSELL ALAN J - Director - Officer CHIEF SCIENTIFIC OFFICER

2023-05-03 18:26:08 -0400 2023-05-01 M 5,208 a 177,793 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

CARRUTHERS R MICHAEL - Officer CHIEF FINANCIAL OFFICER

2023-05-03 18:26:15 -0400 2023-05-01 M 5,208 d 10,417 direct

CARRUTHERS R MICHAEL - Officer CHIEF FINANCIAL OFFICER

2023-05-03 18:26:15 -0400 2023-05-01 M 5,208 a 17,462 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

MOORE JOHN R - Officer GENERAL COUNSEL

2023-05-03 18:26:36 -0400 2023-05-01 M 5,208 d 10,417 direct

MOORE JOHN R - Officer GENERAL COUNSEL

2023-05-03 18:26:36 -0400 2023-05-01 M 5,208 a 8,462 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

DERAKHSHAN BEHRAD - Officer CHIEF BUSINESS OFFICER

2023-05-03 18:26:49 -0400 2023-05-01 M 5,208 d 10,417 direct

DERAKHSHAN BEHRAD - Officer CHIEF BUSINESS OFFICER

2023-05-03 18:26:49 -0400 2023-05-01 M 5,208 a 8,767 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

KOCH KEVIN - Director - Officer PRESIDENT AND CEO

2023-05-03 18:25:43 -0400 2023-05-01 M 10,416 d 20,834 direct

KOCH KEVIN - Director - Officer PRESIDENT AND CEO

2023-05-03 18:25:43 -0400 2023-05-01 M 10,416 a 10,416 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

DONOVAN JOANNE M. - Officer CMO

2023-05-03 18:25:48 -0400 2023-05-01 M 10,416 d 20,834 direct

DONOVAN JOANNE M. - Officer CMO

2023-05-03 18:25:48 -0400 2023-05-01 M 10,416 a 13,214 direct 1.7838 -0.1574 3.9874 5 -0.1574 6

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 22:15:04 UTC 4.6439 0.4161 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 21:45:04 UTC 4.6439 0.4161 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 21:15:03 UTC 4.6439 0.4161 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 20:45:04 UTC 4.6439 0.4161 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 20:15:06 UTC 4.6439 0.4161 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 19:45:04 UTC 4.6439 0.4161 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 19:15:21 UTC 4.6439 0.4161 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 18:45:03 UTC 4.6439 0.4161 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 18:15:04 UTC 4.6439 0.4161 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 17:45:03 UTC 4.6439 0.4161 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 17:15:05 UTC 4.6439 0.4161 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 16:45:04 UTC 4.6551 0.4149 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 16:15:04 UTC 4.6551 0.4149 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 15:45:03 UTC 4.6551 0.4149 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 15:15:04 UTC 4.6551 0.4149 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 14:45:04 UTC 4.6551 0.4149 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 14:15:03 UTC 4.6551 0.4149 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 13:45:04 UTC 4.6551 0.4149 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 13:15:04 UTC 4.6551 0.4149 1000000
EDGEWISE THERAPEUTICS INC EWTX 2023-05-31 12:45:04 UTC 4.6551 0.4149 1000000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund EWTX -700.0 shares, $-4669.0 2023-03-31 N-PORT

No recent transactions

*** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

Elevate your investments